Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7697993 | 0.98 | TAAR1 (0.48) | TAAR1ADRA2AADRA2BADRA2CSMN1; SMN2 | |
| SCHEMBL2886265 | 0.89 | TAAR1 (0.52) | TAAR1ADRA2AADRA2BADRA2CSMN1; SMN2 | |
| SCHEMBL2886363 | 0.87 | TAAR1 (0.50) | TAAR1ADRA2AADRA2BADRA2CSMN1; SMN2 | |
| SCHEMBL7198596 | 0.87 | TAAR1 (0.50) | TAAR1ADRA2AADRA2BADRA2CSMN1; SMN2 | |
| SCHEMBL2886309 | 0.85 | TAAR1 (0.48) | TAAR1ADRA2AADRA2BADRA2CSMN1; SMN2 | |
| SCHEMBL2888284 | 0.85 | TAAR1 (0.48) | TAAR1ADRA2AADRA2BADRA2CSMN1; SMN2 | |
| SCHEMBL2885625 | 0.85 | TAAR1 (0.48) | TAAR1ADRA2AADRA2BADRA2CSMN1; SMN2 | |
| SCHEMBL2886603 | 0.85 | TAAR1 (0.48) | TAAR1ADRA2AADRA2BADRA2CSMN1; SMN2 | |
| SCHEMBL2886419 | 0.85 | TAAR1 (0.48) | TAAR1ADRA2AADRA2BADRA2CSMN1; SMN2 | |
| SCHEMBL2883324 | 0.85 | TAAR1 (0.48) | TAAR1ADRA2AADRA2BADRA2CSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322624-B1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-21 | — | — | EP | claimed |
| EP-1667635-A4 | SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-01-23 | — | — | EP | claimed |
| US-7169795-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-01-30 | — | — | US | claimed |
| US-7091201-B2 | Arylalkane-sulfonamides having endothelin-antagonist activity | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-15 | — | — | US | claimed |
| EP-1667635-A2 | SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-06-14 | — | — | EP | claimed |
| WO-2005048922-A2 | SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-02 | — | — | WO | claimed |
| US-20050096309-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-05-05 | — | — | US | claimed |
| US-20040102464-A1 | Arylalkane-sulfonamides having endothelin-antagonist activity | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-05-27 | — | — | US | claimed |
| EP-1322624-A1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | Actelion Pharmaceuticals Ltd. (CH) | 2003-07-02 | — | — | EP | claimed |
| WO-2002024665-A1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | ACTELION PHARMACEUTICALS LTD (CH) | 2002-03-28 | — | — | WO | claimed |
| EP-0262147-B1 | SELF-DOPED POLYMERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1993-06-23 | — | — | EP | claimed |
| WO-2024181959-A1 | PHARMACEUTICAL COMPOSITION FOR CYTOSTATIC AND RADIATION TREATMENT OF CANCER | Козловский, Вадим Алексеевич | 2024-09-06 | — | — | WO | disclosed |
| CN-110520134-B | Sterile formulations comprising stabilized phosphorothioate oligonucleotides | 基因信号国际公司 | 2023-07-18 | — | — | CN | disclosed |
| US-7857999-B2 | Crosslinked self-doping type electrically conducting polymer, production process thereof, product coated with the polymer and electronic device | SHOWA DENKO K.K. (JP) | 2010-12-28 | — | — | US | disclosed |
| EP-2207185-A1 | Crosslinked self-doping type electrically conducting polymer, production process thereof, product coated with the polymer and electronic device | SHOWA DENKO KABUSHIKI KAISHA (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-20050096309-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-05-05 | — | — | US | disclosed |
| US-20040102464-A1 | Arylalkane-sulfonamides having endothelin-antagonist activity | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-05-27 | — | — | US | disclosed |
| EP-1322624-A1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | Actelion Pharmaceuticals Ltd. (CH) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002083650-A1 | NOVEL SULFONYLAMINO-PYRIMIDINES | ACTELION PHARMACEUTICALS LTD (CH) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002024665-A1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | ACTELION PHARMACEUTICALS LTD (CH) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102464-A1 | Arylalkane-sulfonamides having endothelin-antagonist activity | EDNRA, EDNRB, ECE2 | TAAR1 93/4885ADRA2A 39/4885ADRA2B 67/4885 |
| US-20050096309-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | TFPI, F12, F5 | TAAR1 4762/4885ADRA2A 4781/4885ADRA2B 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.